None listed
Conditions
Interventions
Drug : The subjects took the Ther-Biotic® Complete capsule®(350mg/capsule, Prothera, Inc., USA) once daily for 8 weeks.
Sponsors
Ajou University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Age >=19 years and <=70 years 2) Diagnosed with diarrhea-predominant IBS according to the Rome III criteria 3) Positive test results of hydrogen breath test or fecal calprotectin level 4) Patients who agreed and completed with informed consent form, and patients who can afford to conduct the study
Exclusion criteria
Exclusion criteria: 1) intake of probiotics including Ther-Biotic® Complete 2) diagnosed gastrointestinal diseases(less than 2 years) other than diarrhea-predominant IBS, such as constipation-predominant IBS, mixed type IBS, Crohn’s disease, celiac disease, ulcerative colitis, or maligmant tumor of the colon) 3) past history of intestinal surgery such as gastrectomy or cholecystectomy (except appendectomy) 4) patients who have history of viral hepatitis(including type A, B, or C), liver cirrhosis, malignancy, chronic kidney disease, congestive heart failure and thyroid disease 5) patients who have red-flag sign, such as rectal bleeding or unintended weight loss 6) intake of medications which affect liver function 7) history of travel to parasite-endemic countries 8) pregnant women or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bristol stool scale;gastrointestinal symptoms(questionnaire);lactulose hydrogen breath test, fecal calprotectin, fecal microbiome | — |
Secondary
| Measure | Time frame |
|---|---|
| safety evaluation(adverse effects, laboratory test, physical examination) | — |
Countries
Korea, Republic of
Contacts
Public ContactKyu-Nam Kim
Ajou University Hospital
Outcome results
None listed